PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD

Phase 3 Completed 141 enrolled Panion & BF Biotech Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess the safety and effectiveness of PBF-1681 for the treatment of Iron Deficiency Anemia in patients with Non-Dialysis Dependent Chronic Kidney Disease.

Timeline

Start: 2020-10-14
Primary completion: 2022-10-28
Completion: 2022-12-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ferric Citrate	Unknown	1 g	—

PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD

Summary

Timeline

Drugs

Indications